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Abstract
Substance use, especially alcoholism, has been recog-
nized as a significant problem in schizophrenic patients,
though only a few studies on the effects of pharmaco-
therapy in these patients have been conducted so far.
The thioxanthene neuroleptic flupenthixol, which can be
given intramuscularly (i.m.) for improving compliance,
has been studied as a possible anti-craving drug both in
animal models of alcoholism and some clinical studies.
Pilot studies suggest that comorbid schizophrenics with
substance use may benefit from treatment with flupen-
thixol. Efficacy of flupenthixol (10–60 mg i.m.) in reduc-
ing alcohol consumption of dual diagnosis patients was
studied in an open 6-month clinical trial in 27 schizo-
phrenics with comorbid alcoholism. Twenty-one pa-
tients entered the intention-to-treat analysis. Fourteen
subjects were completers, 13 dropped out. Six patients
completely abstained from alcohol during treatment. Al-
cohol consumption was significantly reduced compared
to baseline (4 weeks before treatment as measured by
timeline follow-back interview). In general, while pa-
tients showed a marked improvement concerning alco-
hol consumption, only a slight improvement in psycho-
pathology was recorded. Overall tolerability was good.
These data indicate a probable beneficial effect of flupen-
thixol in schizophrenic patients with comorbid alcohol-
ism. Although the efficacy of flupenthixol as an anti-crav-
ing drug in dual diagnosis patients has to be explored in
further studies, the drug may be considered a promising
medication for these patients.
Copyright © 2003 S. Karger AG, Basel
There is substantial evidence now that substance use,
especially alcoholism, is a significant problem in schizo-
phrenia, with prevalence estimates of 30–50% in clinical
samples [9, 21, 38, 46, 48, 49, 62]. The term ‘dual diagno-
sis patients’ has been introduced to describe this type of
patient. High prevalence estimates for alcoholism in
schizophrenia have been reported in numerous clinical
samples and various regions [for reviews see 15, 46, 62,
65, 68, 69]. Prevalence estimates for alcoholism clearly
exceed those for other drugs of abuse but are compara-
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tively high for cannabis and cocaine [49]. Clear evidence
for a significant comorbidity of alcoholism and schizo-
phrenia comes especially from the Epidemiological
Catchment Area Study, which reported a 4-fold increased
risk for alcoholism in schizophrenia [24, 56]. Clinical
studies indicate dual diagnosis schizophrenics to have a
poor prognosis, notorious noncompliance, a young age of
onset, male sex and severe social impairment, among oth-
ers [35, 36, 65].
There is no consistent etiological theory to explain sub-
stance use in schizophrenia [47]. Apart from the self-med-
ication hypothesis [30, 37], the role of neuroleptic side
effects, social variables and specific neurobiological hy-
pothesis (dysregulated neural integration of dopamine
and glutamate signaling in the nucleus accumbens) have
been stressed [8]. None of these hypotheses has been gen-
erally accepted.
The pharmacotherapy of comorbid schizophrenics
with alcoholism has widely been neglected, and very few
prospective controlled clinical trials have been performed
to date [61, 66, 78]. The use of novel antipsychotics in the
treatment of dual diagnosis patients has been advocated
repeatedly [4], but few studies have been conducted so far
[11, 79]. The role of other antipsychotics in relapse pre-
vention of substance use in schizophrenia and the interre-
lationship between changes in psychopathology and sub-
stance use in dual diagnosis patients has not been studied
in great detail. The thioxanthene neuroleptic flupenthix-
ol, a drug with mixed dopamine D1/D2 antagonistic
properties as well as antagonistic properties at the sero-
tonin 5-HT2A receptors [19, 40, 45], which is widely used
for acute and long-term treatment of schizophrenia [20],
has been studied as a possible anti-craving drug in a num-
ber of preclinical and clinical studies.
A broad number of preclinical and animal data suggest
flupenthixol to attenuate the positive reinforcing and dis-
criminative stimulus effects of cocaine [74], to decrease
cocaine intake in rats [31, 43] and to block the discrimina-
tive stimulus and reinforcing effects of cocaine [52]. With
respect to alcohol, animal data in rats also suggest a reduc-
tion of alcohol intake [70]. Flupenthixol has been success-
fully studied in the US as an anti-craving drug in cocaine/
crack consumers [17, 18, 29]. Positive effects of flupen-
thixol on alcohol as well as other drug intake have been
reported in a uncontrolled study on 20 patients who
received a daily dose of 0.5–1 mg flupenthixol on a short-
term basis [53]. However, a recently finished placebo-con-
trolled study in nonpsychotic alcoholics (flupenthixol de-
canoate 10 mg every 14 days) showed unfavorable results
[77].
More specifically, a beneficial effect of flupenthixol
decanoate in dual diagnosis schizophrenics has been re-
ported in a case report [71] and an open clinical trial [58].
More recently, Levin et al. [39] studied flupenthixol deca-
noate (40 mg every 14 days) in schizophrenic patients
who were also cocaine users (n = 8) and demonstrated
increases in cocaine-negative urine analysis, as well as
improved psychopathology (decrease in negative and de-
pressive symptoms).
We report the results of an open controlled clinical trial
to assess possible anti-craving and relapse prevention
effects of flupenthixol in schizophrenic patients with co-
morbid alcohol use.
Methods
This was an open exploratory multicenter 6-month trial without a
control group to investigate the relapse prevention and antipsychotic
efficacy of flupenthixol decanoate in schizophrenic patients with sec-
ondary alcohol abuse or dependency. The primary objective was to
investigate whether a reduction in the average consumption of alco-
hol can be achieved by treatment with flupenthixol decanoate. The
primary efficacy variable was the average quantity of alcohol con-
sumption during treatment with flupenthixol decanoate as compared
to the 4 weeks prior to study entry, measured with the timeline fol-
low-back interview [TFLB; 63]. The study was conducted from July
1997 through December 1999 in 6 psychiatric hospitals in Germany
and Switzerland. Patients were seen on a 4-week basis at seven times
throughout the trial [visit 1 (V1) took place in week 0, visit 7 (V7) in
week 24).
Inclusion Criteria
Patients had to meet the ICD-10 diagnostic criteria for schizo-
phrenia (F 20.0–20.09), be aged between 20 and 55 years and had to
have suffered from moderate to severe alcohol dependence for at
least 2 years (F 10.2). Successful completion of detoxification (no
withdrawal symptoms at baseline) 2 weeks before entering the trial,
negative drug screening, written informed consent, and normal EEG
and ECG readings were also required. At baseline the Munich Alco-
holism Screening Test (MALT) was administered to verify diagnosis
of alcohol dependence [14].
Exclusion Criteria
Psychiatric disorders not consistent with the diagnosis of schizo-
phrenia and concurrent alcohol dependence, neoplasm within the
past 5 years, treatment with flupenthixol in the 3 months prior to the
study, known intolerability of the drug or contraindication of treat-
ment with flupenthixol, administration of long-acting depot neuro-
leptics 4 weeks prior to treatment (haloperidol decanoate: 8 weeks),
abuse of or dependence on other drugs in the last year preceding
treatment, clinically relevant medical or neurological disorders re-
quiring long-term therapy, e.g. insulin-dependent diabetes, severe
impairment of liver function (coagulopathy), advanced liver cirrho-
sis, severe cardiac or pulmonary diseases, renal failure, no fixed
address, concomitant treatment with the following medications:
unregistered medications, all psychoactive, including anticonvulsive
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drugs (exceptions: biperiden, promethazine and/or lormetazepame
for sleep disorders, lorazepam for anxiety, antidepressants if neces-
sary) or medication for treatment of alcoholism including acampro-
sate, naltrexone, clomethiazole were exclusion criteria. Patients who
were scheduled for a standardized inpatient treatment were also
excluded from the trial. The study was conducted according to the
guidelines of Good Clinical Practice (GCP) and approved by the
local Ethics Committees.
Treatment
All subjects were treated with flupenthixol decanoate for a maxi-
mum of 24 weeks. Intramuscular injections of the medication were
administered every 2 weeks. All 27 subjects enrolled received at least
1 injection. Compliance was assured as the injections were adminis-
tered by the investigators. The dose could be adjusted individually
(between 10 and 60 mg every two weeks) according to clinical
demand and the clinician’s decision. The medication was provided
in ampoules containing 0.5 ml = 10 mg flupenthixol decanoate. The
occurrence of a relapse was not an a priori reason for a premature
withdrawal from the study.
Compliance
Blood samples were drawn at visits 3 and 7 for the determination
of serum concentrations.
Efficacy and Safety Variables
All efficacy and safety variables were assessed on a 4-week basis
throughout the trial. A German version of the TFLB protocol [6, 7,
63] was used to assess self-reported alcohol consumption 4 weeks
prior to and throughout the trial. In addition, a German version [42,
54] of the Obsessive Compulsive Drinking Scale (OCDS) was used to
measure craving [1].
Psychopathology was assessed with the Positive and Negative
Syndrome Scale [PANSS; 28] and the Clinical Global Impression
(CGI; NIMH 1976) Scale (secondary variables). Extrapyramidal
symptoms were measured by the AIMS scale [22], changes in social
functioning be thy 8-item self-report social functioning questionnaire
[SFQ; 75].
Statistics
Descriptive statistics were used to evaluate the quantitative vari-
ables. Alcohol consumption, craving and psychopathological status
were analyzed by correlation statistical analyses.
For all quantitative variables, means, standard deviations, mini-
mum, median and maximum were computed. Frequency counts and
percentages were generated for qualitative variables. Repeated mea-
surements of some selected variables were analyzed on an explorato-
ry basis using paired t tests. No confirmatory analyses were con-
ducted. All analyses were conducted with the SAS version 6.12 pro-
gram package.
The intention to treat (ITT) sample included all patients with
baseline values, one injection of the study medication and at least 1
follow-up visit. The valid for efficacy (VfE) group completed the
study according to protocol. Patients who prematurely terminated
the study were included with their last available measurement, which
was then used as final outcome. Changes in variables of special inter-
est were analyzed by t test.
Adverse events were classified according to COSTART and
grouped according to the body systems affected.
Results
During the recruitment period 27 patients were en-
rolled in the trial (safety analysis). Twenty-one subjects
were included in the ITT, of which 14 subjects (the VfE
population) completed the 6-months study period. Thir-
teen patients were dropouts. Reasons for premature ter-
mination were lost to follow-up (n = 7), withdrawal of con-
sent (n = 4), adverse event (severe akathisia; n = 1) and
bad compliance (n = 1).
Baseline demographics are given in table 1. Seventeen
(63%) of the 27 patients were male, 10 (37%) female. In
the VfE group 8 (57%) patients were male, 6 (43%)
female. Mean age of the VfE population was 32.0 (23–58)
years, BMI was 23.5 (17–29.3) kg/m2. With respect to
schizophrenic subtype, most VfE patients were diagnosed
as paranoid subtype (n = 12; 86%), 1 patient had a cata-
tonic (7%), another one a schizoaffective psychosis (7%).
All patients showed marked to severe alcohol depen-
dence. For the ITT sample, 5 (SD 1.12) out of the 6 ICD-
10 criteria were fulfilled (VfE sample: 5.0 B 1.07). MALT
score was 27.64 (B 6.39), indicating severe alcohol de-
pendence.
The 21 ITT patients had had a daily alcohol consump-
tion of more than 150 ml pure alcohol (females: 120 ml)
over a period of several months, 12 patients had had a
maximum consumption of more than 300 (females: 240)
ml on several days a month.
Mean flupenthixol dosage given was 30.4 mg every 2
weeks to the ITT sample (VfE sample: 32.2 mg). Mean
duration of treatment in the VfE group was 170 (166–
183) days. During treatment with flupenthixol, 10 pa-
tients (71%) received short-term concomitant psycho-
pharmacological medication: 6 subjects received biperi-
den, 6 psycholeptics and 4 were on antidepressants (doxe-
pine, amitryptilin, nefazodone, paroxetine). No switch to
benzodiazepines or other drugs of abuse could be de-
tected.
Efficacy
Alcohol Consumption. Fourteen of the 21 patients
(60%) of the ITT sample completed the study. Six of them
remained completely abstinent throughout the trial, 2
patients reported a reduced consumption during treat-
ment compared to baseline, 3 patients were relapsers at 2
or 3 visits, 3 patients on more than 3 visits. Eight patients
were abstinent at study end. Alcohol consumption in stan-
dard drinks/day as measured by TFLB decreased signifi-
cantly over time (fig. 1). In addition, the mean number of
relapses to heavy alcohol consumption and the number of
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Table 1. Sociodemographic baseline
characteristics Demographics VfE
n = 14
ITT
n = 21
Safety
n = 27
Male
Female
Age, years
Height, cm
Weight, kg
BMI, kg/m2
Caucasian
Black
8 (57.1)
6 (42.9)
42.0B10.56
172.93B10.30
70.89B14.70
23.54B3.58
12
2
15 (71.4)
6 (28.6)
43.10B10.59
173.33B9.33
71.40B13.05
23.75B3.37
19
2
17 (63.0)
10 (37.0)
42.22B10.07
172.11B8.78
71.80
24.17
25
2
Smoker
No
Yes
1
13
3
18
4
23
Diagnosis
Schizophrenic subtype
Paranoid
Hebephrenic
Catatonic
Simplex
Schizoaffective
12 (85.7)
–
1 (7.1)
–
1 (7.1)
17 (81.0)
1 (4.8)
1 (4.8)
1 (4.8)
1 (4.8)
20 (74.1)
2 (7.4)
1 (3.7)
1 (3.7)
3 (11.1)
Years since diagnosis 7.36B4.31 8.52B6.56 9.70B7.58
Relapse since diagnosis 4.00B2.80 3.65B2.68 4.00B2.86
Years since last inpatient treatment 2.82B3.12 2.72B3.51 2.45B3.29
Mean B SD or percentages (shown in parentheses).
drinks per relapse decreased after initiation of treatment
(fig. 2). In patients who relapsed, the mean number of
drinks per relapse dropped from 7.7 (B 5.8) drinks to 4.4
(B 3.2) drinks during the initial study phase and re-
mained reduced throughout the study. The percentage of
abstinent days during treatment also increased signifi-
cantly during treatment (fig. 3). Craving scores, as mea-
sured by OCDS, decreased significantly between visits 1
and 2, and continuously remained on a reduced level
throughout treatment (fig. 4).
Psychopathology. General assessment of the VfE sub-
jects as documented in the CGI revealed that at the end of
the study 50% were very much or much improved, 21%
were unchanged or had slightly worsened. In line with
these results, social functioning of the patients as mea-
sured by the SFQ had improved by 30%. The mean sum
scores of the SFQ decreased from 9.07 (V1) to 6.79 (V2)
and ended at 6.18 at V7, indicating an enhanced social
functioning.
Results of the PANSS subscales (positive symptoms,
negative symptoms, global) and the BPRS score only
slightly decreased over time (fig. 5).
Safety Analysis. Out of the 27 patients who received at
least one injection of study medication, 9 subjects (33%)
reported at least 1 adverse event (AE). Six of these indi-
viduals suffered from 1 AE, the remaining three had 2, 3
and 5 AEs. In total, 16 adverse events were recorded: aka-
thisia (19%), nervousness (19%), extrapyramidal symp-
toms (12%), insomnia (6%), neuropathy (6%). Body sys-
tems affected were ‘body as a whole’ (recorded in 25% of
AEs) and ‘digestive’ and ‘special senses’, recorded in 6%.
Of the 16 AEs, 12% were rated as possibly related to study
medication, 43% as probably, 37% as improbably related
to the medication, and 6% as not assessable.
Extrapyramidal motor side effect rating as assessed
with the AIMS was remarkably low. The mean summary
scores (items 1–7) decreased from 1.57 (SD 2.65) at base-
line to 1.14 [2, 54] at V5 but returned to 1.64 [3, 20] at
endpoint (V7). At least 8 subjects of the VfE sample scored
zero at all control visits. The mean global assessment score
was slightly enhanced from 0.71 (SD 1.20) at baseline to
1.50 [3, 32] at V5 and 1.43 [2, 68] at endpoint.
Two subjects showed a significant adverse event (aka-
thisia or parkinsonoid), the former terminated the study
prematurely for this reason.
Flupenthixol in Relapse Prevention in
Alcoholic Schizophrenics
Eur Addict Res 2003;9:65–72 69
Fig. 1. Number of drinks during treatment (ITT sample).
Fig. 2. Number of relapses during treatment. Figures inside bars
indicate total number of patients still participating.
Fig. 3. Number of abstinent days per 4-week interval during treat-
ment.
Fig. 4. Craving scores (mean scores OCDS) during treatment.
Fig. 5. PANSS and BPRS scores during treatment (VFE sample).
Serum concentrations of flupenthixol measured were
rather low and, in some cases, close to the detection limit
(0.1 ng/ml) The mean concentration was 0.21 (0.1–0.46)
ng/ml (V3) and 0.22 ng/ml (0.1–0.83; V7), respectively.
Discussion
Substance use has been recognized as a major problem,
affecting compliance and treatment outcome. A number
of dual diagnosis treatment programs has been introduced
over the past decade for this newly recognized type of
patients [2, 12, 23, 25], while the pharmacotherapy of
these patients has widely been neglected.
The present study was designed to examine possible
relapse prevention effects of the thioxanthene flupenthix-
ol in schizophrenics with comorbid alcoholism, and to
explore a possible interrelationship between improve-
ment of psychopathology and alcohol use. Twenty-seven
patients were included in this 6-month study, 21 patients
were eligible for ITT analysis, 13 patients were dropouts.
The efficacy data from this study as measured by TLFB
[7, 63] showed a significant reduction of alcohol con-
sumption behavior compared to the 4-week baseline peri-
od before treatment. Six patients remained completely
abstinent throughout the trial. In addition, craving as
measured by a visual analogue scale and the OCDS [1,
54], was markedly decreased following initiation of treat-
ment. Results from this exploratory study should be dis-
cussed with caution due to the small number of patients
included and the open label design of the study. Limita-
tions also arise from the dropout rate of approximately
1
2
3
4
5
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50%, which is similar to the dropout rates in pharmaco-
logical studies with anti-craving drugs in nonpsychotic
alcoholics [67]. In addition, the efficacy of craving scales
like the OCDS in predicting relapse in alcoholics has not
been firmly established [34]. Still, the overall observed
clinical effects seem remarkable, especially in the light of
the treatment outcomes and compliance rates in dual
diagnosis schizophrenics (cited above). Interestingly,
while the antialcoholic effect of flupenthixol could clearly
be demonstrated, only a slight improvement in the psy-
chopathology of the substance-using patients could be
noticed. The therapeutic effect of flupenthixol did not
seem to be related to an overall improvement of psycho-
pathology, thus questioning to some extent the self-medi-
cation hypothesis of substance use in schizophrenia [30].
This question deserves further attention. Substance use
has been associated with the patients’ wish to improve
psychopathological symptoms, such as anhedonia [55], or
side effects of neuroleptic treatment. A number of find-
ings question this hypothesis [3], and the empirical evi-
dence is small [65, 72].
Two more general aspects may also be generated from
this study. First, although the mean dosage given (32 mg/
14 days) was higher than the one usually given in relapse
prevention for schizophrenia [20 mg; 32], the serum con-
centrations of flupenthixol measured were lower than
those usually found in schizophrenics [26, 27, 73]. Low
neuroleptic serum concentrations in alcoholic schizo-
phrenics have also been reported in other studies [64] and
may be explained by an accelerated metabolism of the
drug in these patients, but this topic warrants further
studies. For dual diagnosis patients, measurement of plas-
ma levels can be recommended for verifying compliance
or variations in metabolism of neuroleptics.
Second, although dual diagnosis patients are notorious
for noncompliance [65, 68], the dropout rate in this study
was not higher than those in pharmacological studies with
nonpsychotic alcoholics [33]. Clearly, more pharmacolog-
ical studies in dual diagnosis patients following a core pro-
tocol are needed to explore pharmacological options and
risks in these patients.
A consistent theory explaining the apparently increas-
ing number of dual diagnosis patients has not been put
forward, but medication effects clearly play a significant
role in the development and treatment of substance use in
schizophrenia. A number of different pharmacological
treatment options can be discussed with respect to sub-
stance use in schizophrenia: (1) use of conventional anti-
psychotics to improve psychopathology, thus reducing the
relapse risk in dual diagnosis patients; (2) use of atypical
neuroleptics to improve negative symptomatology and
avoid side effects, possibly leading to substance use;
(3) use of antidepressants or other drugs to improve
depression or anhedonia [59, 60, 61], and (4) use of novel
anti-craving drugs, such as acamprosate or naltrexone.
Only the first two options have been addressed in a
number of recent studies. To date, the empirical basis for
psychopharmacology in dual diagnosis patients is small.
The role of ‘conventional’ neuroleptics in the develop-
ment and treatment of substance use in schizophrenia has
been discussed with some concern. On the one hand
researchers have argued them to precipitate or worsen
substance use [61, 76]. Dual diagnosis patients may be
more prone to the side effects of neuroleptic treatment,
such as tardive dyskinesia and, especially, akathisia [10,
13, 57, 62], while in the present study the incidence of
akathisia and extrapyramidal side effects was remarkably
low. On the other hand the empirical basis for a beneficial
effect of atypic neuroleptics such as clozapine in dual
diagnosis patients [44] is very small. Only recently, in a
retrospective survey of 43 patients, clozapine was re-
ported to decrease substance use in schizophrenia [79]. In
addition Drake et al. [11], in an a posteriori analysis of
151 patients with schizophrenia or schizoaffective disor-
der and co-occurring substance use, demonstrated that
patients who received clozapine experienced significant
reductions in the severity of their alcohol abuse. However,
continuous substance use in schizophrenics under treat-
ment with clozapine has been reported in some cases [71].
Since there are no depot formula for atypical neuroleptics
yet, the question of noncompliance, crucial for the treat-
ment of dual diagnosis patients, needs to be considered.
The results of this study are not in line with a recently
published study by Wiesbeck et al. [77], who failed to
demonstrate a clinical efficacy of flupenthixol in nonpsy-
chotic alcoholics. The dosage of flupenthixol used in their
study was much lower than the one used in the schizo-
phrenic patients of the present trial, but differences in
treatment outcome may not only be linked to dosage.
They may also reflect different neurobiological mecha-
nisms underlying the addiction process in schizophrenic
and other alcoholics (e.g., the dopaminergic neurotrans-
mission might function differently). In addiction, toler-
ability of the drug and side effects may also be different in
schizophrenic and nonpsychotic alcoholics.
To date, flupenthixol may be considered to be a prom-
ising medication to study in dual diagnosis schizophren-
ics. In the light of the preclinical evidence, suggesting that
relatively low doses of flupenthixol may attenuate alcohol
and cocaine intake [70], further clinical testing of this
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compound in drug abuse/dependence disorders seems
warranted, and should include a control group. Although
low doses of flupenthixol can also cause extrapyramidal
side effects in some cases [16], the clinical data available
so far suggest that tolerance of flupenthixol is usually good
in patients with substance abuse/dependence disorders.
This is also supported by data from the present study.
Most of the subjects of the ITT sample experienced no or
only minimal EPS. Correspondingly, the mean AIMS
scores at all visits were rather low. This finding is remark-
able in the light of the mean dosage of 32.2 mg/14 days,
which is substantially above the recommended dose of
20 mg/14 days used for relapse prevention [32].
Acknowledgment
The authors wish to thank all participating investigators from the
Munich, Haar and Muenster trial units for their contribution. Fur-
thermore, the excellent administrative work of H. Graumann and of
the monitor P.-J. Tönnes is gratefully acknowledged.
References
1 Anton RF, Moak DH, Latham PK: The Obses-
sive Compulsive Drinking scale: A new method
of assessing outcome in alcoholism treatment
studies. Arch Gen Psychiatry 1996;53:225–
231.
2 Barrowclough C, Haddock G, Tarrier N, Lewis
SW, Koring J, O’Brien R, Schofiled N, McGov-
ern J: Randomized controlled trial of motiva-
tional interviewing, cognitive behavior thera-
py, and family intervention for patients with
comorbid schizophrenia and substance use dis-
orders. Am J Psychiatry 2001;158:1706–1713.
3 Brunette MF, Mueser KT, Xie H, Drake H:
Relationships between symptoms of schizo-
phrenia and substance abuse. J Nerv Ment Dis
1997;185:13–20.
4 Buckley P, Thompson P, Way L, Meltzer IIY:
Substance abuse among patients with treat-
ment-resistant schizophrenia: Characteristics
and implications for clozapine therapy. Am J
Psychiatry 1994;151:385–389.
5 Buckley PF: Novel antipsychotic medications
and the treatment of comorbid substance abuse
in schizophrenia. J Subst Abuse Treat 1997;15:
113–116.
6 Carey KB: Reliability and validity of the Time-
Line Follow-Back Interview among psychiatric
outpatients; A preliminary report. Psychol Ad-
dict Behav 1997;11:26–33.
7 Carney MA, Tennen H, Affleck G, Del Boca
FK, Kranzler HR: Levels and patterns of alco-
hol consumption using timeline follow-back,
daily diaries and real-time ‘electronic inter-
views’. J Stud Alcohol 1998;598:447–454.
8 Chambers RA, Krystal JH, Self DW: A neuro-
biological basis for substance abuse comorbidi-
ty in schizophrenia. Biol Psychiatry 2001;71–
83.
9 Cuffel BJ: Prevalence estimates of substance
abuse in schizophrenia and their correlates. J
Nerv Ment Dis 1992;180:589–592.
10 Dixon L, Weiden PJ, Haas G, Frances AJ:
Increased tardive dyskinesia in alcohol-abusing
schizophrenic patients. Compr Psychiatry
1992;33:121–122.
11 Drake RE, Xie H, McHugo GJ, Green AI: The
effects of clozapine on alcohol and drug use dis-
orders among patients with schizophrenia.
Schizophrenia Bull 2000;26:441–449.
12 Drake RE, Mueser KT: Psychosocial ap-
proaches to dual diagnosis. Schizophrenia Bull
2000;26:105–118.
13 Duke PJ, Pantelis C, Barnes TRE: South West-
minster Schizophrenia Survey. Alcohol Use
and its relationship to symptoms, tardive dys-
kinesia and illness onset. Br J Psychiatry 1994;
164:630–636.
14 Feuerlein W, Ringer CH, Küfner H, Antons K:
Diagnose des Alkoholismus. Der Münchener
Alkoholismustest (MALT): MMW Munchn
Med Wochenschr 1977;119:1275–1282.
15 Fowler IL, Carr VC, Carter NT, et al: Patterns
of current and lifetime substance use in schizo-
phrenia. Schizophrenia Bull 1998;24:443–455.
16 Fritze J, Spueda I: Tolerability of low dose neu-
roleptics: A case control study of flupenthixol.
Eur Neuropsychopharmacol 1997;7:261–266.
17 Gawin FH, Allen D, Humblestone B: Outpa-
tient treatment of ‘crack’ cocaine smoking with
flupenthixol decanoate. Arch Gen Psychiatry
1989;46:322–325.
18 Gawin FH, Khalsa-Denison M, Jatlow P: Flu-
penthixol-induced aversion to crack cocaine. N
Engl J Med 1996;334:1340–1341.
19 Glaser T, Sommermeyer H, Fassbender M,
Mauler F: The receptor binding profile of cis-
flupentixol; in Glaser T, Soyka M (eds): Flu-
pentixol – typisches oder atypisches Wirkspek-
trum? Darmstadt, Steinkopff, 1998 pp 9–21 (in
German).
20 Glaser T, Soyka M (Hrsg): Flupentixol – Phar-
makologie, antipsychotische Wirkung, neue In-
dikationen. Darmstadt, Steinkopff, 1998.
21 Graham HL, Maslin J, Copello A, Birchwood
M, Mueser K, McGovern D, Georgiou G: Drug
and alcohol problems amongst individuals
with severe mental health problems in an inner
city area of the UK. Soc Psychiatry Psychiatr
Epidemiol 2001;448–455.
22 Guy W: Early Clinical Drug Evaluation Assess-
ment Manual for Psychopathology. Rockville,
National institute Mental Health, 1976.
23 Hellerstein DJ, Rosenthal RN, Miner CR: A
prospective study of integrated outpatient
treatment for substance-abusing schizophrenic
patients. Am J Addict 1995;4:33–42.
24 Helzer JD, Pryzbeck TR: The co-occurrence of
alcoholism with other psychiatric disorders in
the general population and its impact on treat-
ment. J Stud Alcohol 1988;49:219–224.
25 Ho AP, Tsuang JW, Liberman RP, Wang R,
Wilkins JN, Eckman TA, Shaner AL: Achiev-
ing effective treatment of patients with chronic
psychotic illness and comorbid substance de-
pendence. Am J Psychiatry 1999;156:1765–
1770.
26 Jørgensen A: Pharmacokinetik studies on flu-
penthixol decanoate, a depot neuroleptic of the
thioxanthene group. Drug Metab Rev 1978;8:
235–249.
27 Jørgensen A: Serum concentrations of cis(Z)-
Flupentixol and prolactin in chronic schizo-
phrenic patients treated with flupentixol and
cis(Z)-Flupentixol decanoate. Psychopharma-
cology (Berl) 1982, 77:58–65.
28 Kay SR, Fiszbein A, Opler LA: The Positive
and Negative Syndrome Scale (PANSS) for
schizophrenics. Development and standardiza-
tion. Schizophr Bull 1987;13:261–276.
29 Khalsa ME, Jatlow P, Gawin FH: Flupenthixol
and desipramine treatment of crack users:
Doule-blind Results; in CPDD Problems of
drug dependence, vol 141, in NIDA Research
Monographs. Washington, Department of
Health and Human Services, pp 438–444.
30 Khantzian EJ: The self-medication hypothesis
of substance use disorders: A reconsideration
and recent applications. Harv Rev Psychiatry
1997;4:231–244.
31 King GR, Joyner C, Ellinwood EH: Contin-
uous or intermittent cocaine administration:
Effects of flupenthixol treatment during with-
drawal. Pharmacol Biochem Behav 1994;49:
883–889.
32 Kissling W: Guidelines for neuroleptic relapse
prevention. New York, Springer, 1991.
33 Kranzler HR, Escobar R, Lee DK, Meza E: Ele-
vated rates of early discontinuation from phar-
macotherapy trials in alcohol and drug abusers.
Alcohol Clin Exp Res 1996;20:16–20.
34 Kranzler HR, Mulgrew CL, Modesto-Lowe V,
Burleson JA: Validity of the Obesessive Com-
pulsive Drinking Scale (OCDS): Does craving
predict drinking behavior? Alcohol Clin Exp
Res 1999;23:108–114.
72 Eur Addict Res 2003;9:65–72 Soyka/Aichmüller/v Bardeleben/Beneke/
Glaser/Hornung-Knobel/Wegner
35 Krausz M, Mass R, Haasen C, Gross J: Psycho-
pathology in patients with schizophrenia and
substance abuse: A comparative clinical study.
Psychopathology 1996;95–103.
36 Krausz M, Vertheim U, Degkwitz P: Psychiat-
ric comorbidity in opiate addicts. Eur Addict
Res 1999;55–62.
37 Krystal JH, D’Souza DC, Madonick S, Petrakis
IL: Toward a rational pharmacotherapy of co-
morbid substance abuse in schizophrenia pa-
tients. Schizophrenia Res 1999;35(suppl):S35–
S49.
38 Lehman AF, Myers CP, Corty E, Thompson
JW: Prevalence and patterns of ‘dual diagnosis’
among psychiatric inpatients. Compr Psychia-
try 1994:35:1–5.
39 Levin FR, Evans SM, Coomaraswammy S,
Collins ED, Regent N, Kleber HD: Flupenthix-
ol treatment for cocaine abusers with schizo-
phrenia: A pilot study. Am J Drug Alcohol
Abuse 1998;24:343–360.
40 Leysen JE, Janssen PMF, Schotte A, Luyten
MHML, Megens AAHP: Interaction of antip-
sychotic drugs with neurotransmitter receptor
sites in vitro and in vivo in relation to pharma-
cological and clinical effects: Role of 5HT2
receptors. Psychopharmacology (Berl) 1993;
112:40–54.
41 Linszen DH, Dingemans PM, Lenior ME: Can-
nabis abuse and the course of recent-onset
schizophrenic disorders. Arch Gen Psychiatry
1994;51:273–279.
42 Mann K, Ackermann K: Die OCDS-G: Psy-
chometrische Kennwerte der deutschen Ver-
sion der Obsessive Compulsive Drinking Scale.
Sucht 2000;90–100.
43 Mansbach RS, Jortani SA, Balster RL: Antago-
nism of cocaine’s reinforcing and discrimina-
tive stimulus effects by ·-flupenthixol. Exp
Clin Psychopharmacol 1994;2:3–12.
44 Markus P, Snyder R: Reduction of comorbid
substance abuse with clozapine. Am J Psychia-
try 1995;152:959.
45 Meltzer HY, Matsubara S, Lee JC: Classifica-
tion of typical and atypical antipsychotic drugs
on the basis of dopamine D-1, D-2 and seroto-
nin2 pKi values. J Pharmacol Exp Ther 1989;
251:238–246.
46 Mueser KT, Bellack AS, Blanchard JJ: Comor-
bidity of schizophrenia and substance abuse:
Implications for treatment. J Consul Clin Psy-
chol 1992;60:845–856.
47 Mueser KT, Drake RE, Wallach MA: Dual
Diagnosis: A review of etiological theories. Ad-
dict Behav 1998;23:717–734.
48 Mueser KT, Yarnold PR, Levinson DF, Singh
H, Bellack AS, Kee K, Morrison RL, Yadalam
KG: Prevalence of substance abuse in schizo-
phrenia: Demographic and clinical correlates.
Schizophrenia Bull 1990;16:31–56.
49 Mueser KT, Yarnold PR, Rosenberg SD, Swett
C, Miles KM, Hill D: Substance use disorder in
hospitalized severely mentally ill psychiatric
patients: Prevalence, correlates, and sub-
groups. Schizophrenia Bull 2000, 26:179–192.
50 Mueser KT, Yarnold PR, Bellack AS: Diagnos-
tic and demographic correlates of substance
abuse: Implications for treatment. J Consult
Clin Psychol 1992b;60:845–856.
51 Negus SS, Gatch MB, Mello NK: Discrimina-
tive stimulus effects of a cocaine/heroin ‘speed-
ball’ combination in rhesus monkeys. J Phar-
macol Exp Ther 1998;285:1123–1136.
52 Negus SS, Mello NK, Lamas X, Mendelson JH:
Acute and chronic effects of flupenthixol on the
discriminative stimulus and reinforcing effects
of cocaine in rhesus monkeys. J Pharmacol Exp
Ther 1996;278:879–889.
53 Nespor K, Prokes B, Brozek P, Barta´kova´ O,
Peka´rkova´ M: Flupentixol in the treatment of
dependence (preliminary communication).
Ceska Slovenska Psychiatrie 1999;6:387–390
(in Polish).
54 Preuss UW, Schütz CG, Koch J, Soyka M: Psy-
chometrische Erfassung von subjektivem Crav-
ing mit der Obsessive Compulsive Drinking
Scale (OCDS) und Einflüsse von Befindlichkeit
und Persönlichkeit. Suchtmed 1999;1:33–38.
55 Pristach CA, Smith CM: Self-reported effects
of alcohol use on symptoms of schizophrenia.
Psychiatry Serv 1996;47:421–423.
56 Regier DA, Farmer ME, Rae DS, et al: Comor-
bidity of mental disorders with alcohol and oth-
er drug abuse: Results from the epidemiologica
catchment area (ECA) study. JAMA 1990;264:
2511–2518.
57 Salyers MP, Mueser KT: Social functioning,
psychopathology, and medication side effects
in relation to substance use and abuse in
schizophrenia. Schizophrenia Res 48;109–
123.
58 Schilkrut R, Cabrera J, Morales E, Herrera L:
Neuroleptics in the treatment of drug depen-
dence in schizophrenics: A study with flupen-
thixol decanoate. Psychopharmacology (Berl)
1988;96:342 (abstract).
59 Siris SG, Bermanzohn PC, Mason SE, Shuwall
MA: Antidepressant for substance-abusing pa-
tients: A minireview. Prog Neuropsychophar-
macol Biol Psychiatry 1991;15:1–13.
60 Siris SG, Mason SE, Bermanzohn PC, Shuwall
MA, Aseniero A: Dual diagnosis/psychiatric
comorbidity of drug dependence: Epidemiolo-
gy and treatment. Psychopharmacol Bull 1993;
29:127–133.
61 Siris SG: Pharmacological treatment of sub-
stance abusing schizophrenic patients. Schizo-
phrenia Bull 1990;16:111–122.
62 Smith J, Hucker S: Schizophrenia and Sub-
stance Abuse. Br J Psychiatry 1994;165:13–
21.
63 Sobell LC, Sobell MB: Timeline follow-back: A
technique for assessing self-reported alcohol
consumption; in Litten RZ, Allen JP (eds):
Measuring Alcohol Consumption: Psychoso-
cial and Biochemical Methods. Towota, Hu-
mana Press, 1992 pp 41–72.
64 Soni SD, Brownlee M: Alcohol abuse in
chronic schizophrenics: Implications for man-
agement in the community. Acta Psychiatr
Scand 1991;84:272–276.
65 Soyka, M, Alcoholism and Schizophrenia. Ad-
diction 2000;95:1613–1618.
66 Soyka M: Dual diagnosis in patients with
schizophrenia. Issues in pharmacological treat-
ment. CNS Drugs 1996;6:414–425.
67 Soyka M: Relapse prevention in patients with
alcoholism: Recent advantages and future pos-
sibilities. CNS Drugs 1997;7:313–327.
68 Soyka M: Substance abuse, psychiatric disor-
der and disturbed behavior. Br J Psychiatry
2000;176:345–350.
69 Soyka M, Albus M, Finelli A, et al: Prevalence
of alcohol and drug abuse in schizophrenic
inpatients. Eur Arch Psychiatry Clin Neurosci
1993;242:362–372.
70 Soyka M, de Vry J: Flupenthixol as a potential
pharmacotreatment of alcohol and cocaine
abuse/dependence. Eur Neuropsychopharma-
col, 2000;10:325–332.
71 Soyka M, Sand P: Successful treatment with
flupenthixol decanoate of a patient with both
schizophrenia and alcoholism. Pharmacopsy-
chiatry 1995;28:64–65.
72 Soyka M, Albus M, Immler B, Kathmann N,
Hippius H: Psychopatholgy in dual diagnosis
and non-addicted schizophrenics – Are there
differences? Eur Arch Psychiatry Clin Neurosci
2001;251:232–238.
73 Stauning JA, Kirk L, Jørgensen A: Comparison
of serum levels after intramuscular injections
of 2 and 10% cis(Z)-Flupentixol decanoate in
viscoleo to schizophrenic patients. Psycho-
pharmacology (Berl) 1979;65:69–72.
74 Spealman RD, Bergman J, Madras BK, Meila
KF: Discriminative stimulus of cocaine in
squirrel monkeys: Involvement of dopamine
receptor subtypes. J Pharmacol Exp Ther 1991;
258:945–953.
75 Tyrer P: Measurement of social functioning; in
Tyrer P, Casey P (eds): Social Function in Psy-
chiatry. The Hidden Axis of Classification Ex-
posed. Petersfield, Wrightson Biomedical Pub-
lishing, 1993:21–52.
76 Vorungati LN, Heslegrave RJ, Awad AG: Neu-
roleptic dysphoria may be the missing link
between schizophrenia and substance abuse. J
Nerv Ment Dis 1997;185:463–465.
77 Wiesbeck GA, Weijers HG, Lesch OM, Glaser
T, Toennes PJ, Boening J: Flupenthixol deca-
noate and relapse prevention in alcoholics: Re-
sults from a placebo-controlled study. Alcohol
Alcohol 2001;329–334.
78 Wilkins JN: Pharmacotherapy of schizophre-
nia patients with comorbid substance abuse.
Schizophrenia Bull 1997;23:215–228.
79 Zimmet SV, Strous Rd, Burgess ES, Kohn-
stamm S, Green AI: Effects of clozapine on
substance use in patients with schizophrenia
and schizoaffective disorder: A retrospective
survey. J Clin Psychopharmacol 2000;20:94–
98.
